Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 2-FDCK or 2C-B or Carvedilol

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (1) · Coreg, Coreg CR (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)
classes:
2C-x series (1) · Dissociative (1) · Phenethylamine (1) · Psychedelic (1) · Research material (1) · with alpha-1 antagonism)]] (1) · [[:Category:Antihypertensives|Antihypertensive]] (1) · [[:Category:Beta blockers|Beta blocker (non-selective (1) · [[:Category:Heart failure medicines|Heart failure medicine]] (1)
mechanism:
5-HT2A partial agonist (1) · NMDA antagonist; fluorinated ketamine analogue (1) · '"`UNIQ--vote-00000015-QINU`"' CYP2D6 metabolism produces stereoselective clearance; CYP2D6 poor metabolizers have higher plasma exposure and may need lower doses'"`UNIQ--ref-00000016-QINU`"'. (1)
uses:
None (2) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1)
starting dose:
None (2) · Heart failure: 3.125 mg PO BID, doubling every 2 weeks as tolerated to target 25 mg BID (50 mg BID if >85 kg). Hypertension: 6.25 mg PO BID, titrate to 25 mg BID (1)
preparations:
None (2) · IR tablets 3.125, 6.25, 12.5, 25 mg; Coreg CR capsules 10, 20, 40, 80 mg (once-daily) (1)
fda max:
None (2) · 50 mg BID in heart failure (or once-daily equivalent CR); 25 mg BID in hypertension (1)
routes:
None (1) · insufflated (1) · Oral (2) · PR (1)
onset:
None (1) · 45-75 min (oral) (1) · Antihypertensive effect within 1 week; heart-failure mortality benefit accrues over months of titration (1)
duration:
None (1) · 4-8 h (1) · ~12 hours (IR); 24 hours (CR) (1)
halflife:
None (1) · 7-10 hours'"`UNIQ--ref-0000001B-QINU`"' (1) · Not well characterized (1)
bioavailability:
None (1) · Not well characterized (1) · ~25-35% (extensive first-pass), increased by food which slows absorption and reduces orthostatic risk'"`UNIQ--ref-0000001C-QINU`"' (1)
pregnancy:
None (1) · Limited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 3 results in range #1 to #3.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

2


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"